

CLAIM AMENDMENTS

Claims 1 through 11 (canceled)

1 12. (previously presented) A method of treating
2 colorectal carcinoma in a patient in need of said treatment, which
3 comprises the step of administering to said patient, a
4 therapeutically effective amount of 4-[1-{2-(6-methyl-2-
5 pyridinyl)ethyl-4- piperidinyl}carbonyl]methane-sulfoanilide 2HCl
6 sufficient to treat the colorectal carcinoma.

1 13. (currently amended) The method of treating
2 colorectal carcinoma in a patient as defined in claim 12, wherein
3 prior to treating the patient with a therapeutically effective
4 amount of 4-[1-{2-(6-methyl-2-pyridinyl)ethyl-4-
5 piperidinyl}carbonyl]methane-sulfoanilide 2HCl, the following steps
6 are carried out:

7 (a) obtaining from the patient a biopsy of colorectal
8 tissue, lymph nodes or a sample of body fluid or stool, wherein the
9 colorectal tissue, lymph nodes, body fluid, or stool are free of
10 HERG channels in a patient free of colorectal cancer;

11 (b) detecting as a selective tumor marker any
12 presence of at least one HERG potassium channel in the biopsy of
13 colorectal tissue, lymph nodes, or in the body fluid or stool; and

14 (c) relating [[the]] any presence of at least one HERG
15 potassium channel in the biopsy or sample [[to]] as indicating that
16 colorectal carcinoma is present in the patient.